Zacks: Brokerages Anticipate Allakos Inc (ALLK) to Post -$0.24 Earnings Per Share
Analysts forecast that Allakos Inc (NASDAQ:ALLK) will post earnings of ($0.24) per share for the current quarter, according to Zacks. Zero analysts have made estimates for Allakos’ earnings, with estimates ranging from ($0.26) to ($0.21). The company is expected to report its next quarterly earnings results on Wednesday, December 5th.
According to Zacks, analysts expect that Allakos will report full year earnings of ($1.07) per share for the current fiscal year, with EPS estimates ranging from ($1.20) to ($0.93). For the next fiscal year, analysts expect that the firm will post earnings of ($1.21) per share, with EPS estimates ranging from ($1.50) to ($0.92). Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that cover Allakos.
Allakos (NASDAQ:ALLK) last announced its earnings results on Wednesday, August 29th. The company reported ($4.17) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.27) by ($3.90).
ALLK stock traded up $0.65 during mid-day trading on Monday, reaching $43.11. 144,686 shares of the stock traded hands, compared to its average volume of 256,147. Allakos has a 52-week low of $26.00 and a 52-week high of $49.10.
In other news, major shareholder Venture Fund (Ohi Rivervest II acquired 111,111 shares of Allakos stock in a transaction on Monday, July 23rd. The stock was bought at an average cost of $18.00 per share, with a total value of $1,999,998.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Daniel Janney acquired 250,000 shares of Allakos stock in a transaction on Monday, July 23rd. The shares were purchased at an average cost of $18.00 per share, with a total value of $4,500,000.00. The disclosure for this purchase can be found here.
An institutional investor recently bought a new position in Allakos stock. Strs Ohio purchased a new position in Allakos Inc (NASDAQ:ALLK) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 2,400 shares of the company’s stock, valued at approximately $107,000.
Allakos Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis.
Further Reading: Price to Earnings Ratio (PE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Allakos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allakos and related companies with MarketBeat.com's FREE daily email newsletter.